J. Goldman & CO LP Cti Biopharma Corp Call Options Transaction History

J. Goldman & CO LP

  • $3.21 Billion
  • Q3 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$4.45 - $6.17 $901,125 - $1.25 Million
202,500 New
202,500 $1.22 Million
Q2 2022

Aug 15, 2022
SELL
$3.55 - $6.27 $239,625 - $423,225
-67,500 Reduced 50.0%
67,500 $403,000
Q1 2022

May 16, 2022
BUY
$1.9 - $5.23 $256,500 - $706,050
135,000 New
135,000 $630,000

About CTI BIOPHARMA CORP

CTIC Quotes by TradingView
  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email